Accessibility Menu
Tarsus Pharmaceuticals logo

Tarsus Pharmaceuticals(NASDAQ) TARS

Current Price$57.61
Market Cap$2.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+180%
5 Year+122%
1 Year+36%
1 Month-9%
Tarsus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 57.582026-07-22
Tarsus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.14%USD 57.502026-07-15
1 month-9.41%USD 63.562026-06-22
3 month-5.56%USD 60.972026-04-23
Year to date-29.68%USD 81.882025-12-31
1 year+35.99%USD 42.342025-07-22
3 year+133.87%USD 24.622023-07-21
5 year+122.23%USD 25.912021-07-23
Since inception+179.79%USD 20.582020-10-16

Tarsus Pharmaceuticals Financials at a Glance

Market Cap

$2.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$535.08M

Net Income (TTM)

-$48.27M

EPS (TTM)

-$1.13

P/E Ratio

-50.80

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$57.61

Volume

202

Open

$58.39

Previous Close

$57.61

Daily Range

$57.07 - $58.76

52-Week Range

$38.51 - $85.25

Estimated Earnings Date

Aug 6, 2026

TARS News

SellAlert-Red.png

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade

Jonathan PoncianoMar 24, 2026
optometrist testing patients vision (1)

Why Shares of Tarsus Pharmaceuticals Are Up Thursday

James HalleyJul 20, 2023

TARS: Motley Fool Moneyball Superscore

82

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tarsus Pharmaceuticals

Tarsus makes medicine for common eye and skin issues. Its main product kills tiny mites that cause red eyelids. The company also develops tablets to prevent Lyme disease.

What Tarsus Makes

  • XDEMVY: Eye drop treatment for eyelid inflammation caused by tiny mites; this is the first and only medicine approved for this condition.
  • TP-04: Investigational gel for ocular rosacea, a chronic disease that causes redness and visible blood vessels around the eyes.
  • TP-05: Oral tablet designed to kill ticks quickly to prevent the transmission of Lyme disease to humans.
  • Lotilaner: Active chemical ingredient used across all products to paralyze and kill parasites without affecting human nerve cells.

Moving Fast and Growing

  • Launched XDEMVY in the U.S. market in August 2023 with a specialized sales force.
  • Partnered with GrandPharma to handle the development and sale of its main eye treatment in China.
  • Started a Phase 2 clinical trial for its eye redness treatment in December 2025.
  • Introduced television advertising in 2025 to increase public awareness of eyelid mite infestations.

Targeting the Root Cause

Tarsus focuses on killing the parasites that cause disease rather than just treating the symptoms. Its main technology uses a specific chemical that targets the nervous systems of mites and ticks while remaining safe for people.

Measuring Recent Success

  • Revenue reached $151.7 million in Q4 2025, up 128.4% year-over-year.
  • Gross profit hit $140.7 million in Q4 2025, up 128.9% from Q4 2024.
  • Operating cash flow rose to $19.3 million in Q4 2025, up 187.1% from the previous year.
  • Free cash flow reached $13 million in Q4 2025, up 147.6% year-over-year.
  • Net product sales for the full year 2025 totaled $451.4 million.

The Big Picture

Tarsus has transitioned from a clinical research firm into a commercial company with a growing revenue stream from its first approved eye treatment. Its long-term strategy involves applying its parasite-killing technology to unmet needs in skin care and infectious disease prevention.

AI Generated • Apr 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

370

CEO

Bobak Azamian, MD, PhD

Website

tarsusrx.com

Headquarters

Irvine, CA 92618, US

TARS Financials

Key Financial Metrics (TTM)

Gross Margin

90.44%

Operating Margin

-9.50%

Net Income Margin

-9.02%

Return on Equity

-14.19%

Return on Capital

-16.24%

Return on Assets

-8.31%

Earnings Yield

-1.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

43.02M

Volume

202

Avg. Volume

971.09K

Financials (TTM)

Gross Profit

$483.93M

Operating Income

-$50.81M

EBITDA

-$40.18M

Operating Cash Flow

-$16.45M

Capital Expenditure

-$15.09M

Free Cash Flow

-$31.54M

Cash & ST Invst.

$388.73M

Total Debt

$88.68M

Tarsus Pharmaceuticals Performance Analysis

Tarsus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 25,816,000-54.7%
20232023-12-31USD 17,447,000-32.4%
20242024-12-31USD 182,953,000948.6%
20252025-12-31USD 451,360,000146.7%
Tarsus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3031.1%
Q32025-09-3015.6%
Q42025-12-3127.8%
Q12026-03-316.8%
Tarsus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.52274.9%
20232023-12-31USD -4.6283.4%
20242024-12-31USD -3.07-33.6%
20252025-12-31USD -1.59-48.3%
Tarsus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3025.0%
Q32025-09-3037.5%
Q42025-12-3133.3%
Q12026-03-3120.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$162.05M

+106.9%

Gross Profit

$152.66M

+108.8%

Gross Margin

94.20%

N/A

Market Cap

$2.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.70M

N/A

Employees

370

N/A

Net Income

-$6.97M

+72.3%

EBITDA

-$6.75M

+69.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$388.73M

-4.7%

Total Debt

$88.68M

+22.5%

Accounts Receivable

$117.21M

+82.7%

Inventory

$4.57M

+69.0%

Long Term Debt

$88.68M

+23.2%

Short Term Debt

$0.00

-100.0%

Return on Assets

-8.31%

N/A

Return on Invested Capital

-11.61%

N/A

Free Cash Flow

-$30.47M

-43.4%

Operating Cash Flow

-$24.65M

-19.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZLABZai Lab Limited
$20.50+0.10%
IRONDisc Medicine, Inc.
$74.32-1.67%
AAPGAscentage Pharma Group International
$19.24+0.71%
ARQTArcutis Biotherapeutics, Inc.
$27.90-1.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About TARS

What is the current price of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals is trading at $57.61 per share.

What is the 52-week range for Tarsus Pharmaceuticals?

Over the past 52 weeks, Tarsus Pharmaceuticals has traded between $38.51 and $85.25.

How much debt does Tarsus Pharmaceuticals have?

As of the most recent reporting period, Tarsus Pharmaceuticals reported total debt of $88.68M.

How much cash does Tarsus Pharmaceuticals have on hand?

Tarsus Pharmaceuticals reported $102.19M in cash and cash equivalents in its most recent financial results.

What is Tarsus Pharmaceuticals’s dividend yield?

Tarsus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services